Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · IEX Real-Time Price · USD
1.28
+0.05 (4.51%)
Nov 29, 2023, 9:52 AM EST - Market open
4.51%
Market Cap 144.99M
Revenue (ttm) 102.90M
Net Income (ttm) -208.39M
Shares Out 113.72M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 514,670
Open 1.22
Previous Close 1.22
Day's Range 1.21 - 1.28
52-Week Range 0.70 - 8.87
Beta 0.30
Analysts Buy
Price Target 9.83 (+670.98%)
Earnings Date Nov 7, 2023

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK... [Read more]

Sector Healthcare
IPO Date Jun 26, 2013
Employees 199
Stock Exchange NASDAQ
Ticker Symbol ESPR
Full Company Profile

Financial Performance

In 2022, ESPR's revenue was $75.48 million, a decrease of -3.79% compared to the previous year's $78.45 million. Losses were -$233.66 million, -13.17% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $9.83, which is an increase of 670.98% from the latest price.

Price Target
$9.83
(670.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Caus...

15 days ago - GlobeNewsWire

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis –

17 days ago - GlobeNewsWire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs) under ...

19 days ago - GlobeNewsWire

Esperion Reports Third Quarter 2023 Financial Results

– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Mome...

22 days ago - GlobeNewsWire

Esperion to Participate in Jefferies London Healthcare Conference

ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief Executi...

4 weeks ago - GlobeNewsWire

American College of Cardiology Program to Increase Cholesterol Screenings

Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL

2 months ago - GlobeNewsWire

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President...

3 months ago - GlobeNewsWire

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 –

3 months ago - GlobeNewsWire

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates o...

3 months ago - GlobeNewsWire

Esperion Reports Second Quarter 2023 Financial Results

– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded Indi...

4 months ago - GlobeNewsWire

Esperion to Participate in BTIG Virtual Biotechnology Conference 2023

ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, ...

4 months ago - GlobeNewsWire

Esperion to Report Second Quarter 2023 Financial Results on August 1

ANN ARBOR, Mich., July 17, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023.

4 months ago - GlobeNewsWire

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2...

5 months ago - GlobeNewsWire

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

– Seeking inclusion of CV risk reduction indications in Europe –  – Anticipated approvals in Europe in the first half of 2024 –  ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: E...

5 months ago - GlobeNewsWire

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in a...

5 months ago - GlobeNewsWire

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists' (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observe...

5 months ago - GlobeNewsWire

Esperion to Present New Key Science at the American Diabetes Association's 83rd Scientific Sessions 2023

ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association's 83rd Scientific Sessio...

6 months ago - GlobeNewsWire

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time fo...

6 months ago - GlobeNewsWire

Esperion to Participate in Jefferies Healthcare Conference

ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the Jeffe...

6 months ago - GlobeNewsWire

Esperion Reports First Quarter 2023 Financial Results

– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with ...

7 months ago - GlobeNewsWire

Esperion to Participate in JMP Securities Life Sciences Conference

ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Secur...

7 months ago - GlobeNewsWire

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesd...

7 months ago - GlobeNewsWire

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

–  Performance-Based Agreement Provides for Currax's 72 Sales Representatives to Detail Esperion's Products –

8 months ago - GlobeNewsWire

Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham's 22nd An...

8 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ENOVEWTXSENSSLS
8 months ago - Benzinga